To evaluate the association between serum soluble urokinase-type plasminogen activator receptor (suPAR) and chronic kidney disease (CKD) by Meta-analysis.

Data updated by December 1, 2020 in PubMed, Web of Science, Embase and Cochrane Library, CNKI and Wanfang databases were researched. The data were extracted independently by two reviewers and the quality analysis was performed by NOS or AHRQ. Statistical analysis was performed with STA-TA 16.0 and the R programming language.

There were 21 studies fulfilling the criteria. The Meta-analysis results showed that: serum suPAR concentration was negatively correlated with glomerular filtration rate(r=-0.67, 95%CI: -0.93--0.40) and had positively relativity with the level of proteinuria(r=0.20, 95%CI: 0.12~0.29), however it was less influenced by eGFR in patients with primary glomerular disease or early stage of CKD. The higher serum suPAR concentration might lead to proteinuria(HR=2.48, 95%CI: 1.88-3.27) and renal function injuried(HR=1.36, 95%CI: 1.26-1.47) which indicated the incidence of CKD. Elevated serum suPAR was significantly related to increased development of CKD(HR=1.44, 95%CI: 1.26-1.66) and increased all-cause mortality(HR=1.39, 95%CI: 1.16-1.66) and increased cardiovascular events(HR=2.39, 95%CI: 1.28-4.48)).

The higher serum suPAR increases the risk of mortality, cardiovascular in patients with CKD. Monitoring serum suPAR concentrations may be used for prognosis for the incidence and progression of CKD.

Receptors, Urokinase Plasminogen Activator; Chronic Kidney Disease; Primary Glomerular Diseases